EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer

Ricardo Rodrigues iD, Beatriz Garcia iD, Miguel Rito iD, Rúben Roque iD, Teresa Pereira, Sónia Morgado, Vanessa Tavares, Tiago Nunes da Silva, Valeriano Leite iD, Branca Maria Cavaco iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ricardo Rodrigues und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Ba…. Hauptthemen laut MEDLINE: Pyrimidinones, Oximes, Pyridones, Imidazoles. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior, iNOVA4Health - Programme in Translational Medicine, Associated Laboratory LS4FUTURE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with poor response to standard therapies. While Dabrafenib plus Trametinib (DT) combination therapy has improved the survival of patients with BRAF-mutant ATC, resistance remains a challenge. Given the association of macrophages with poor prognosis, and that SPRY4 has emerged as a mediator in ATC–macrophage interactions, we investigated their role in DT resistance and evaluated the therapeutic potential of macrophage targeting. Transwell co-cultures of BRAF-mutant ATC cell lines (T235 and T238) with THP-1-derived macrophages were established, and viability, invasion, and macrophage phenotype were assessed. Macrophages were also characterised in tumour samples from eleven ATC patients treated with DT. In vitro, DT significantly reduced ATC cell viability and invasion. However, macrophage co-culture significantly restored these effects, also promoting cytoskeletal remodelling and increased vimentin expression, despite DT treatment. DT significantly downregulated SPRY4 and suppressed MAPK signalling and PD-L1. These effects were also significantly reversed by macrophages. Under DT, macrophages showed an increase in M2-like polarisation in co-culture. Patients’ tumour samples were highly infiltrated with macrophages. In vitro targeting of macrophages with Edicotinib, in combination with DT, significantly enhanced the anti-tumour effects of DT and decreased the M2-like polarisation, bypassing the macrophage-mediated DT resistance. Overall, the in vitro findings suggest that macrophages modulate ATC response to DT by enhancing viability, invasion, MAPK signalling and PD-L1, supporting a pro-tumoural phenotype. Targeting macrophages overcomes this resistance, highlighting the CSF1/CSF1R signalling pathway within the ATC–macrophage axis as a promising therapeutic target to improve DT efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinonesOximesPyridonesImidazolesThyroid Carcinoma, AnaplasticDrug Resistance, NeoplasmMacrophagesThyroid NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansCell Line, TumorProto-Oncogene Proteins B-rafCoculture TechniquesCell Survival

Stichwörter der Autor:innen

Dabrafenib plus TrametinibSPRY4anaplastic thyroid carcinomamacrophages

Substanzen

PyrimidinonesOximesPyridonesImidazolestrametinibdabrafenibProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
  • Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal.
  • Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Campus da Caparica, 2829-516 Caparica, Portugal.
  • Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
  • Instituto de Anatomia Patológica, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Escola Superior de Saúde de Lisboa, Politécnico de Lisboa, Estrada de Benfica, 529, 1549-020 Lisboa, Portugal.

ORCID-Profile: Ricardo Rodrigues, Beatriz Garcia, Miguel Rito, Rúben Roque, Valeriano Leite, Branca Maria Cavaco

Förderung

  • Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior
  • iNOVA4Health - Programme in Translational Medicine
  • Associated Laboratory LS4FUTURE
  • Associação de Endocrinologia Oncológica (AEO)
  • Instituto Português de Oncologia de Lisboa Francisco Gentil
  • iNOVA4Health Research Unit
  • iNOVA4Health—Programme in Translational Medicine

Zitieren

APA

Rodrigues, R., Garcia, B., Rito, M., Roque, R., Pereira, T., Morgado, S., Tavares, V., da Silva, T. N., Leite, V., & Cavaco, B. M. (2026). Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177691

Vancouver

Rodrigues R, Garcia B, Rito M, Roque R, Pereira T, Morgado S, et al. Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177691

BibTeX
@article{Rodrigues2026,
  author = {Rodrigues, Ricardo and Garcia, Beatriz and Rito, Miguel and Roque, Rúben and Pereira, Teresa and Morgado, Sónia and Tavares, Vanessa and da Silva, Tiago Nunes and Leite, Valeriano and Cavaco, Branca Maria},
  title = {Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177691}
}
Kostenlos starten →